News

The phase 1a study is a first in-human trial evaluating SYX-5219 for AD.

John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.

A 30-year-old patient with dermatofibrosarcoma protuberans faced a recurrence after initial surgery. Mohs micrographic surgery was used for precise excision, reducing recurrence risk and improving outcomes.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Tezepelumab reduced CSU activity post-treatment through week 32, suggesting a delayed, sustained TSLP blockade effect.

Participants experienced smoother, younger-looking skin after just 1 session, with results lasting up to 16 weeks.

The investigational drug, designed using AI technology, optimizes pharmacologic characteristics for psoriasis treatment.

According to a survey, both patients and clinicians are unsatisfied with the current therapeutic landscape and are looking for options that better fulfill patient needs.

The expert discussion focused on patient management strategies, treatment modalities, and the role of multidisciplinary collaboration.

Valerie Harvey, MD, MPH, FAAD, discusses pigmentary disorders like melasma and hyperpigmentation, highlighting their disproportionate impact on women, particularly those with skin of color.

This review of the latest dermatologic studies includes insights into supporting laser tattoo removal for adults impacted by the justice-system, a case of blastic plasmacytoid dendritic cell neoplasm, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

In part 1 of this Frontline Forum supplement, experts discuss the burden of HS, reducing diagnostic delays, and more.

According to a clinical trial and in vitro study, TTFE can promote scalp health and hair growth by 96.88% while reducing inflammation.

A pilot study revealed that mitochondrial complex I-blocking drugs, like metformin and berberine, improved TSW symptoms in most participants.

A comprehensive evaluation of therapies found that lasers were most effective with high rates of patient satisfaction.

Discover the latest research from the AAD poster hall, compiled in one place for dermatology professionals.

Join Dermatology Times in celebrating the women who make this field shine through their patient interactions, clinical insights, and research.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Explore a comprehensive roundup of the most important AAD late breakers, all in one place – key insights from the latest dermatology research.

Patients observed a 56% reduction in lesions after 56 days of treatment with only mild adverse events.

Experts stressed the importance of dermatologists engaging in climate advocacy and adopting sustainable practices, as their actions may inspire others to follow suit.

Tomassian noted unrealistic beauty standards fueled by social media filters and edited images have led to distorted expectations.

Incyte’s phase 3 STOP-HS trials demonstrated significant efficacy and safety of povorcitinib in moderate to severe hidradenitis suppurativa.

Cryo-EM reveals molecular mechanisms of clindamycin resistance in Cutibacterium acnes, highlighting key mutations affecting antibiotic binding.

Explore the top headlines of the week including insights on L'Oréal’s voluntary recall of benzoyl peroxide products, the impact of GLP-1 medications on skin health, and more 2025 conferences.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about the FDA voluntary benzoyl peroxide recalls, the National Eczema Association's strategic efforts, recaps of this week’s AAD Annual Meeting, and more.

This week, we feature top articles from our sister publications on FDA updates, Medicaid pricing, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.